Market Overview

Looking Into Trxade Group's Return On Capital Employed


Looking at Q3, Trxade Group (NASDAQ: MEDS) earned $145.82 thousand, a 127.24% increase from the preceding quarter. Trxade Group's sales decreased to $6.33 million, a 3.96% change since Q2. In Q2, Trxade Group brought in $6.59 million in sales but lost $535.28 thousand in earnings.

Why ROCE Is Significant

Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q3, Trxade Group posted an ROCE of 0.01%.

Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.

Return on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.

For Trxade Group, the return on capital employed ratio shows the number of assets can actually help the company achieve higher returns, an important note investors will take into account when gauging the payoff from long-term financing strategies.

Q3 Earnings Recap

Trxade Group reported Q3 earnings per share at $0.02/share, which did not meet analyst predictions of $0.03/share.


Related Articles (MEDS)

View Comments and Join the Discussion!

Posted-In: Earnings News